Perspective Therapeutics 2025 net loss widens on higher R&D costs
Overview
US radiopharmaceutical developer's 2025 net loss widened on higher R&D spending
Grant revenue declined yr/yr, while operating expenses rose 24%
Company raised $164 mln in February 2026 equity offering to fund operations into late 2027
Outlook
Company expects to present clinical updates for all programs at medical conferences throughout 2026
Perspective Therapeutics expects cash and investments to fund operations into late 2027
Result Drivers
R&D SPENDING - Higher research and development expenses, mainly from increased clinical site activities, drug program and delivery costs, and personnel expenses, drove the wider net loss
ASSET IMPAIRMENT - A $10 mln non-cash impairment loss was recorded after deprioritizing an early-stage preclinical asset
GRANT REVENUE DECLINE - Grant revenue decreased to $0.9 mln from $1.5 mln yr/yr, reflecting lower receipts from NIH-funded work
Company press release: ID:nGNX5Bhhyr
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Grant Revenue |
| $884,000 |
|
FY EPS |
| -$1.40 |
|
FY Net Income |
| -$103.12 mln |
|
FY Net Income from Cont Ops |
| -$104.43 mln |
|
FY Operating Income |
| -$113.56 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Perspective Therapeutics Inc is $12.00, about 140% above its March 13 closing price of $5.00
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
